X

DECATYLEN LOZENGE

Product Information

Registration Status: Active

SIN04783P

DECATYLEN LOZENGE is approved to be sold in Singapore with effective from 1990-06-25. It is marketed by APEX PHARMA MARKETING PTE LTD, with the registration number of SIN04783P.

This product contains Dequalinium Chloride 0.25mg, and Dibucaine 0.03mg in the form of LOZENGE. It is approved for ORAL use.

This product is manufactured by Acino Pharma AG in SWITZERLAND.

It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.

Product Reference
Loading...



Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


Description

A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)

Indication

For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.

Mechanism of Action

Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.

Pharmacokinetics

Absorption
In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
Distribution
Metabolism
Primarily hepatic.
Elimination

Toxicity

Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.

Active Ingredient/Synonyms

2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide | 2-Butoxy-N-(alpha-diethylaminoethyl)cinchoninamide | 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide | 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide | 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide | 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide | 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide | alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine | alpha-Butyloxycinchoninic acid diethylethylenediamide | CINCHOCAINE | Cinchocainum | Cincocainio | Dibucaine | Dibucaine base | N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide | Cinchocaine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!